

Asian American Medical Group Returns To The Black With S\$0.6M Net Profit For FY2015; Revenue Up 65% On Strong Demand For Liver Treatment Services

Singapore, 20 October 2015 – ASX-listed Asian American Medical Group Limited (“AAMG” and together with its subsidiaries, the “Group”) announced today a net profit of S\$0.6 million for the 12 months ended 31 August 2015 (“FY2015”), reversing the previous year’s net loss of S\$2.5 million, thanks to a surge in demand for its liver treatment services. AAMG’s Asian American Blood & Bone Marrow Transplant Centre Pte Ltd (“AABMTC”) ceased operations on 31 December 2014 and was classified under discontinued operations. The Group recorded a \$0.5 million loss from discontinued operations. Without this loss, the Group would have achieved a net profit of \$1.0 million from continuing operations in FY2015.

Revenue rose 65.2% to S\$20.4 million from S\$12.3 million in FY2014, driven mainly by contributions from the Group’s wholly owned Asian American Liver Centre (“AALC”), which performed substantially more liver dialysis and surgical procedures during the year. AALC successfully carried out 11 living donor liver transplantations in FY2015, up from five in the previous year.

The increase in liver transplantation and surgical activities resulted in higher in-patient billings, sales of medication and professional consultation fees. This enabled AALC, which accounted for 95.8% of the Group’s revenue, to achieve a net profit of S\$1.3 million, compared to a net loss of S\$1.9 million in FY2014.

The Group’s Management and Consultancy (“M&C”) segment recorded revenue of S\$0.8 million, up from S\$0.2 million in FY2014. This was due mainly to consultancy services provided to Rich Tree Land (“RTL”), for the development of the Zhuhai-Singapore Life Science Park, a specialist ambulatory medical centre for advanced diagnostics and wellness services in Zhuhai, China. The M&C segment, which accounted for 4.1% of the Group’s FY2015 revenue, recorded a net profit of S\$0.3 million.

The Group’s newly established radiation oncology practice, run by its subsidiary Asian American Radiation Oncology (“AARO”), generated revenue of S\$42,000 in the first five months of operation. AARO, established in April, incurred a loss of S\$0.1 million during those months due to development costs.

The Group’s net assets increased S\$3.2 million to S\$8.5 million, due mainly to the placement of 30 million new shares to a group of investors during the year under review. Net asset value per share rose to 3.55 Singapore cents from 2.52 cents.

The Group achieved earnings of 0.49 Singapore cent a share from continuing operations, compared to a loss of 1.09 Singapore cents a share in FY2014.

For personal use only

Dato' Dr Tan Kai Chah, Executive Chairman of AAMG, said: "Our positive financial performance underscores AAMG's capabilities as a premium healthcare service provider as we continue to grow our various business segments. We are gaining traction in the region and are very excited about our inroads into new markets such as China."

The Group announced on 12 August 2015 its intention to acquire a 60% stake in RTL, the developer of the Zhuhai-Singapore Life Science Park. Given Zhuhai's close proximity to Macau and Hong Kong, and its easy accessibility with the upcoming Hong Kong-Macau-Zhuhai Bridge, AAMG believes the centre will reshape medical tourism in Southern China over the next decade.

"Our vision is to be a leading healthcare provider in Asia-Pacific. This will require us to constantly move up the value chain and take on projects that can generate higher returns. Backed by our partnership with UPMC, we are hopeful of achieving sustainable growth and enhancing value for shareholders over the long term," Dr Tan said.

AAMG has been partnering renowned U.S. healthcare group UPMC since 2012. Leveraging on this tie-up, AARO has initiated projects in Myanmar and Russia through telemedicine, and is exploring opportunities in Malaysia, China and Vietnam.

- End of Press Release -

About Asian American Medical Group

Asian American Medical Group ("AAMG") is based in Singapore and has been listed on the Australian Securities Exchange since September 2009. The Group's operations include the Asian American Liver Centre Pte Ltd ("AALC"), established in 1994 in Singapore, and Asian American Radiation Oncology Pte Ltd ("AARO").

The Group entered into a strategic collaboration in October 2012 with the US-based US\$12-billion integrated global health enterprise UPMC. UPMC, ranked No. 12 on the U.S. News & World Report Honor Roll of American's Best Hospitals, is affiliated with the University of Pittsburgh Schools of the Health Sciences and are pioneers in the field of transplantation. This collaboration has enhanced AAMG's clinical capabilities through shared protocols, rigorous quality standards and technology and also created a platform for AAMG to expand into other countries in Asia such as Malaysia and Myanmar.

AALC, one of Asia's foremost liver centres, is led by renowned hepatobiliary expert and liver transplant surgeon, Dato' Dr. Tan Kai Chah (Dr. KC Tan), who helped start the Liver Transplant Programme at the King's College Hospital London, UK, and pioneered the highly successful Living Donor Liver Transplantation (LDLT) Programme in Singapore. In 2004, AALC begun conducting surgical procedures at iHEAL Medical Centre, located in Kuala Lumpur, Malaysia.

AARO, established in March 2015, offers radiation oncology clinical, consultancy and management services and is spearheaded by Dr Daniel Tan Yat Harn. Based in Singapore, AARO will drive

For personal use only

expansion into the growing radiotherapy and oncology segment in the overseas market, at a time where there is a shortage of modern radiotherapy treatment centres.

For further information, please visit www.aamg.co.

Media enquiries

WeR1 Consultants

Ms Sheryl Sim; sheryl@wer1.net

Ms Rachael De Foe; rachaeldefoe@wer1.net

Tel: +65 6737 4844

For personal use only